earnings
confidence high
sentiment neutral
materiality 0.50
Nkarta reports Q2 net loss of $23M, cash of $334M; NKX019 data expected H2 2025
Nkarta, Inc.
2025-Q2 EPS
reported -$0.74
vs consensus -$0.36
▼ miss
(-104.4%)
- Net loss of $23.0M ($0.31 per share) for Q2 2025.
- Cash, equivalents and investments of $334.0M as of June 30, 2025; runway into 2029.
- R&D expenses of $20.8M; G&A expenses of $6.4M for Q2 2025.
- Preliminary NKX019 autoimmune data (Ntrust-1 and Ntrust-2) expected H2 2025.
- Shawn Rose, M.D., Ph.D appointed Chief Medical Officer and Head of R&D in June 2025.